New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding ...

We are navigating political interference, institutional instability, and growing uncertainty across the cancer research ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

Immunotherapy let some cancer patients with mismatch repair deficient tumors completely avoid surgery, chemo and radiation, a ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

The session follows the American Association for Cancer Research's prior call to action against executive orders that would ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

A new, small cancer study may give hope to patients with solid tumors in the stomach, esophagus or rectum. The standard ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...